Two Sigma Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $851K | Sell |
212,700
-23,700
| -10% | -$94.8K | ﹤0.01% | 1518 |
|
|
2025
Q1 | $752K | Buy |
236,400
+218,500
| +1,221% | +$695K | ﹤0.01% | 1602 |
|
|
2024
Q4 | $95.8K | Sell |
17,900
-43,400
| -71% | -$232K | ﹤0.01% | 2224 |
|
|
2024
Q3 | $324K | Sell |
61,300
-52,100
| -46% | -$275K | ﹤0.01% | 1881 |
|
|
2024
Q2 | $206K | Sell |
113,400
-71,700
| -39% | -$130K | ﹤0.01% | 2207 |
|
|
2024
Q1 | $329K | Sell |
185,100
-50,500
| -21% | -$89.9K | ﹤0.01% | 2037 |
|
|
2023
Q4 | $415K | Sell |
235,600
-13,300
| -5% | -$23.4K | ﹤0.01% | 1990 |
|
|
2023
Q3 | $363K | Buy |
248,900
+70,100
| +39% | +$102K | ﹤0.01% | 1915 |
|
|
2023
Q2 | $409K | Sell |
178,800
-8,500
| -5% | -$19.5K | ﹤0.01% | 1877 |
|
|
2023
Q1 | $170K | Sell |
187,300
-73,000
| -28% | -$66.4K | ﹤0.01% | 2297 |
|
|
2022
Q4 | $221K | Sell |
260,300
-219,800
| -46% | -$187K | ﹤0.01% | 2156 |
|
|
2022
Q3 | $393K | Buy |
480,100
+106,700
| +29% | +$87.3K | ﹤0.01% | 1946 |
|
|
2022
Q2 | $370K | Sell |
373,400
-43,800
| -10% | -$43.4K | ﹤0.01% | 2051 |
|
|
2022
Q1 | $684K | Sell |
417,200
-346,200
| -45% | -$568K | ﹤0.01% | 1828 |
|
|
2021
Q4 | $1.84M | Buy |
+763,400
| New | +$1.84M | ﹤0.01% | 1242 |
|
|
2021
Q3 | – | Sell |
-288,300
| Closed | -$770K | – | 2477 |
|
|
2021
Q2 | $770K | Sell |
288,300
-3,700
| -1% | -$9.88K | ﹤0.01% | 1754 |
|
|
2021
Q1 | $899K | Buy |
+292,000
| New | +$899K | ﹤0.01% | 1714 |
|
|
2020
Q3 | – | Sell |
-36,880
| Closed | -$100K | – | 2437 |
|
|
2020
Q2 | $100K | Buy |
36,880
+8,000
| +28% | +$21.7K | ﹤0.01% | 2357 |
|
|
2020
Q1 | $61K | Buy |
28,880
+12,300
| +74% | +$26K | ﹤0.01% | 2361 |
|
|
2019
Q4 | $90K | Buy |
+16,580
| New | +$90K | ﹤0.01% | 2258 |
|